Skip to content

Comparison of oral prednisolone and ACTH therapies in infantile epileptic spasms syndrome: using BASED and E-Chess scores.

Aug 2026 · Brain & development (Tokyo. 1979) · Vol 48 5, pp. 104587 · 0 citations · 32 references
Medicine

TL;DR

High-dose oral prednisolone and ACTH therapies demonstrated comparable efficacy in reducing electrographic and clinical seizure burden in children with IESS and improvement in epileptiform activity, as reflected by reductions in the BASED score is strongly associated with better clinical outcomes.

Abstract

Objective

This study aimed to compare the efficacy of adrenocorticotropic hormone (ACTH) and oral prednisolone therapies in children with infantile epileptic spasms syndrome (IESS), utilizing the Burden of Amplitudes and Epileptiform Discharges (BASED) score to assess electrographic severity and the Early Childhood Epilepsy Severity Scale (E-Chess) to evaluate clinical outcomes.

Methods

This retrospective cross-sectional study included 40 children aged 1 to 16 months with IESS. Children received either ACTH (n = 23) or high-dose oral prednisolone (n = 17). Electroencephalographic severity was assessed before treatment and on day 28 post-treatment using the BASED score. Clinical epilepsy severity was evaluated at one year post-treatment using the E-Chess score.

Results

Both treatment groups showed significant reductions in BASED scores (overall cohort p < 0.001; ACTH group p < 0.001; prednisolone group p = 0.007). However, there was no statistically significant difference between the ACTH and prednisolone groups regarding post-treatment BASED or E-Chess scores. While clinical factors such as gender, age, and etiology were not associated with favorable outcomes, a lower post-treatment BASED score was significantly associated with a better clinical prognosis (p = 0.007). Notably, a higher number of pretreatment anti-seizure medications (ASMs) was a strong predictor of poor clinical outcome (OR: 5.474, 95% CI: 1.849-16.207; p = 0.002).

Conclusion

High-dose oral prednisolone and ACTH therapies demonstrated comparable efficacy in reducing electrographic and clinical seizure burden in children with IESS. Improvement in epileptiform activity, as reflected by reductions in the BASED score, is strongly associated with better clinical outcomes. Additionally, a high pretreatment medication burden may serve as an early indicator of a refractory clinical course.

View source

Similar papers

Review Aug 2026

Efficacy of synthetic ACTH in confirmed and presumed monogenic developmental and epileptic encephalopathies.

It is suggested that ACTH may be associated with sustained electroclinical improvement in selected genetically defined DEEs, and the identified network-level interactions between ion channel-related genes and intracellular signaling pathways provide a potential molecular framework for understanding variability in treat...

Çisem Duman Kayar, Sinan Akbaş, Fulya Kürekçi et al. · 0 citations
Aug 2026

Time over drug in pediatric status epilepticus: A prospective observational study.

BACKGROUND Convulsive status epilepticus (CSE) is a time-sensitive neurological emergency in which delayed treatment may contribute to pharmacoresistance and poor outcomes. Evidence comparing third-line antiseizure medications in children remains limited. Objective To compare intravenous lacosamide and phenytoin in ped...

Michael Nabil Halim, Rasha Hussein Aly Hussein, O. El-Rashidy et al. · 0 citations
Review Open access Sep 2026

Effectiveness and safety of cannabidiol in adult patients with epilepsy: A multicenter, retrospective study

Abstract Objective Cannabidiol (CBD) has demonstrated promising effectiveness and tolerability as adjunctive treatment in patients with severe childhood epilepsies. This study investigated the effectiveness and tolerability of CBD in adults with a history of Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), or tuber...

Sara Sánchez-Gamino, María Isabel Chamorro Muñoz, P. Serrano-Castro et al. · 0 citations
Open access Sep 2026

Long‐term developmental outcome in infantile epileptic spasms syndrome after high‐dose prednisolone and vigabatrin treatment

Abstract Objective To evaluate long‐term developmental outcomes and identify independent predictors of favorable developmental outcomes at 3 years of age in children with infantile epileptic spasms syndrome (IESS) treated with a standardized stepwise vigabatrin and high‐dose prednisolone protocol. Methods This prospect...

Soyoung Jang, Hui-Jin Shin, Se Hee Kim et al. · 0 citations
Open access Aug 2026

Impact of vigabatrin on risk of relapse of infantile spasms

Abstract Objective Vigabatrin is an effective treatment for infantile epileptic spasms syndrome (IESS), but relapse remains a clinical challenge. The ideal dose and duration of treatment after response are unknown. We set out to identify treatment‐related predictors of IESS relapse after initial vigabatrin response. Me...

Yaretson I Carmenate, Hayoung E Ahn, Haley Peters et al. · 0 citations
Open access Aug 2026

Pediatric developmental epileptic encephalopathies treated with cenobamate: Real-world outcomes across etiologies, syndromes, and seizure types.

OBJECTIVE This study was undertaken to assess cenobamate (CNB) effectiveness, tolerability, and dosing in pediatric developmental and epileptic encephalopathies (DEEs), testing prespecified hypotheses on response by syndrome, etiology, electroencephalographic pattern, seizure type, CNB dose (mg/kg/day), and concomitant...

Á. Aledo-Serrano, Adrián Valls-Carbó, E. González-Alguacil et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.